6945.TWO
Price:
$53
Market Cap:
$4.50B
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other...[Read more]
Industry
Biotechnology
IPO Date
2023-07-14
Stock Exchange
TWO
Ticker
6945.TWO
According to AP Biosciences Inc’s latest financial reports and current stock price. The company's current PE Ratio is -9.43. This represents a change of 27.59% compared to the average of -7.39 of the last 4 quarters.
The mean historical PE Ratio of AP Biosciences Inc over the last ten years is 2.44K. The current -9.43 PE Ratio has changed -138.70% with respect to the historical average. Over the past ten years (40 quarters), 6945.TWO's PE Ratio was at its highest in in the December 2024 quarter at -5.38. The PE Ratio was at its lowest in in the March 2023 quarter at -21.63.
Average
2.44K
Median
-9.10
Minimum
-20.28
Maximum
12.24K
Discovering the peaks and valleys of AP Biosciences Inc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 12.24K
Minimum Annual Increase = -100.17%
Minimum Annual PE Ratio = -20.28
Year | PE Ratio | Change |
---|---|---|
2024 | -8.86 | -2.66% |
2023 | -9.10 | -36.77% |
2022 | -14.40 | -29.03% |
2021 | -20.28 | -100.17% |
The current PE Ratio of AP Biosciences Inc (6945.TWO) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-10.79
5-year avg
2.44K
10-year avg
2.44K
AP Biosciences Inc’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AP Biosciences Inc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like AP Biosciences Inc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is AP Biosciences Inc's PE Ratio?
How is the PE Ratio calculated for AP Biosciences Inc (6945.TWO)?
What is the highest PE Ratio for AP Biosciences Inc (6945.TWO)?
What is the 3-year average PE Ratio for AP Biosciences Inc (6945.TWO)?
What is the 5-year average PE Ratio for AP Biosciences Inc (6945.TWO)?
How does the current PE Ratio for AP Biosciences Inc (6945.TWO) compare to its historical average?